Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genmab ( (GMAB) ) has issued an announcement.
Genmab A/S has reported a change in its shareholder structure, disclosing on April 14, 2026, that Orbis Investment Management Limited held, as of April 13, 2026, 3,114,318 shares in the company. This stake corresponds to 4.85% of Genmab’s share capital and voting rights, crossing the Danish regulatory threshold for major shareholder notification under Section 30 of the Danish Capital Markets Act.
The announcement formalizes Orbis as a significant institutional investor in Genmab, underscoring continued interest from global asset managers in the Danish biotech group. While the disclosure does not alter Genmab’s day‑to‑day operations, it is relevant for governance transparency and may be closely watched by existing shareholders tracking ownership concentration in the Nasdaq‑listed antibody specialist.
The most recent analyst rating on (GMAB) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Neutral.
The score is supported by strong financial performance (rapid growth, high margins, solid cash generation) and a constructive earnings outlook with meaningful pipeline catalysts, but is held back by the sharp 2025 leverage increase and weaker earnings quality signals, plus bearish near-term technical momentum despite oversold readings.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is an international biotechnology company focused on developing innovative antibody medicines to improve the lives of people with cancer and other serious diseases. Founded in 1999 and headquartered in Copenhagen, the company has built a broad portfolio of antibody-based formats, including bispecifics, ADCs and immune-modulating antibodies, powering eight approved medicines and a robust late-stage clinical pipeline across North America, Europe and Asia Pacific.
Average Trading Volume: 1,729,892
Technical Sentiment Signal: Hold
Current Market Cap: $17.36B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.